EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms

Mohammad Yasin Zamanian iD, Hamidreza Zafari, Maria K Osminina, Alla A Skakodub, Raed Fanoukh Aboqader Al-Aouadi, Maryam Golmohammadi, Nikta Nikbakht, Iman Fatemi

Animal Models and Experimental Medicine · 2025-01 · 8 (1) · 5-19

DOI: 10.1002/ame2.12518 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Animal Models and Experimental Medicine, online erschienen am 03.12.2024. Verfasst von Mohammad Yasin Zamanian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran. Hauptthemen laut MEDLINE: Liposomes, Arthritis, Rheumatoid, Dexamethasone, Anti-Inflammatory Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects approximately 0.46% of the global population. Conventional therapeutics for RA, including disease‐modifying antirheumatic drugs (DMARDs), nonsteroidal anti‐inflammatory drugs (NSAIDs), and corticosteroids, frequently result in unintended adverse effects. Dexamethasone (DEX) is a potent glucocorticoid used to treat RA due to its anti‐inflammatory and immunosuppressive properties. Liposomal delivery of DEX, particularly when liposomes are surface‐modified with targeting ligands like peptides or sialic acid, can improve drug efficacy by enhancing its distribution to inflamed joints and minimizing toxicity. This study investigates the potential of liposomal drug delivery systems to enhance the efficacy and targeting of DEX in the treatment of RA. Results from various studies demonstrate that liposomal DEX significantly inhibits arthritis progression in animal models, reduces joint inflammation and damage, and alleviates cartilage destruction compared to free DEX. The liposomal formulation also shows better hemocompatibility, fewer adverse effects on body weight and immune organ index, and a longer circulation time with higher bioavailability. The anti‐inflammatory mechanism is associated with the downregulation of pro‐inflammatory cytokines like tumor necrosis factor‐α (TNF‐α) and B‐cell–activating factor (BAFF), which are key players in the pathogenesis of RA. Additionally, liposomal DEX can induce the expression of anti‐inflammatory cytokines like interleukin‐10 (IL‐10), which has significant anti‐inflammatory and immunoregulatory properties. The findings suggest that liposomal DEX represents a promising candidate for effective and safe RA therapy, with the potential to improve the management of this debilitating disease by providing targeted delivery and sustained release of the drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesArthritis, RheumatoidDexamethasoneAnti-Inflammatory AgentsInflammationAnimalsDrug Delivery Systems

Stichwörter der Autor:innen

TNF‐αdexamethasoneinflammationliposomerheumatoid arthritis

Substanzen

LiposomesDexamethasoneAnti-Inflammatory Agents

Autor:innen und Institutionen

  • Department of Physiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Department of Pharmacology and Toxicology, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran.
  • Department of Orthopedic Surgery, Joint Reconstruction Research Center, Imam Khomeini Hospital Complex, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Pediatric department, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University), Moscow, Russian Federation.
  • Department of Pediatric Preventive Dentistry E.V. Borovsky, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University), Moscow, Russian Federation.
  • Department of Medicine, College of Medicine, Al-Ayen Iraqi University, Thi-Qar, Iraq.

ORCID-Profile: Mohammad Yasin Zamanian

Zitieren

APA

Zamanian, M. Y., Zafari, H., Osminina, M. K., Skakodub, A. A., Al-Aouadi, R. F. A., Golmohammadi, M., Nikbakht, N., & Fatemi, I. (2025). Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms. Animal Models and Experimental Medicine, 8(1), 5-19. https://doi.org/10.1002/ame2.12518

Vancouver

Zamanian MY, Zafari H, Osminina MK, Skakodub AA, Al-Aouadi RFA, Golmohammadi M, et al. Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms. Animal Models and Experimental Medicine. 2025;8(1):5-19. doi:10.1002/ame2.12518

BibTeX
@article{Zamanian2025,
  author = {Zamanian, Mohammad Yasin and Zafari, Hamidreza and Osminina, Maria K and Skakodub, Alla A and Al-Aouadi, Raed Fanoukh Aboqader and Golmohammadi, Maryam and Nikbakht, Nikta and Fatemi, Iman},
  title = {Improving dexamethasone drug loading and efficacy in treating rheumatoid arthritis via liposome: Focusing on inflammation and molecular mechanisms},
  journal = {Animal Models and Experimental Medicine},
  year = {2025},
  volume = {8},
  number = {1},
  pages = {5--19},
  doi = {10.1002/ame2.12518}
}
Kostenlos starten →